ENTRADA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.88 USD | +2.81% |
|
+17.13% | -8.02% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.02% | 438M | - | ||
| +10.44% | 106B | B+ | ||
| +0.82% | 104B | B+ | ||
| +6.72% | 23.25B | B | ||
| -13.89% | 22.5B | B+ | ||
| -6.64% | 18.7B | A- | ||
| -37.26% | 17.95B | A- | ||
| -10.98% | 16.99B | B | ||
| +8.67% | 14.26B | C+ | ||
| +41.08% | 12.76B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- TRDA Stock
- Ratings Entrada Therapeutics, Inc.